@article {1519, title = {Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model.}, journal = {The Journal of allergy and clinical immunology}, volume = {120}, year = {2007}, month = {2007 Nov}, pages = {1146-52}, abstract = {Omalizumab (trade name Xolair) is approved by the US Food and Drug Administration for treatment of moderate-to-severe allergic asthma. Given the high acquisition cost of omalizumab, its role and cost-effectiveness in disease management require definition.}, keywords = {Anti-Allergic Agents, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Asthma, Cost-Benefit Analysis, Humans, Models, Theoretical, Severity of Illness Index}, issn = {1097-6825}, doi = {10.1111/j.1524-4733.2010.00763.x}, author = {Wu, Ann C and Paltiel, A David and Kuntz, Karen M and Weiss, Scott T and Fuhlbrigge, Anne L} }